Loxo Oncology Enters Strategic Pact with AmoyDx, PREMIA

Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Co., has entered into a strategic partnership agreement with AmoyDx and PREMIA Holdings, under which, AmoyDx and PREMIA will provide large-scale cancer patient screening in Asia to support the ongoing clinical development of LOXO-292, Loxo Oncology’s RET (rearranged during transfection) kinase inhibitor which leverages AmoyDx’s multi-gene polymerase chain reaction (PCR) and next-gen sequencing (NGS) panels to identify patients with this rare genetic alteration. 

"We are extremely pleased to announce this important strategic collaboration with Loxo Oncology. The number of targeted therapies on actionable genomic alterations is increasing rapidly, with an ever-growing number of Asian patients and physicians at the forefront of participating in and leading novel cancer drug development in this arena," said Wenn Sun, Ph.D., founder and president of PREMIA and Li-Mou Zheng, Ph.D., founder and chief executive officer of AmoyDx. "AmoyDx and PREMIA are uniquely positioned in China and Japan to create the fastest and most efficient patient identification and enrollment network."   

-----------------------------------------------------------------------
Editor's Note:

If you have any suggestion to the content, 

please email: Julia.Zhang@ubmsinoexpo.com